Wall Street Zen Downgrades Adaptive Biotechnologies (NASDAQ:ADPT) to Hold

Adaptive Biotechnologies (NASDAQ:ADPT) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research firms also recently issued reports on ADPT. JPMorgan Chase & Co. upped their price target on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. BTIG Research increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Piper Sandler lifted their price target on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average price target of $17.22.

Adaptive Biotechnologies Stock Up 0.7%

NASDAQ ADPT opened at $18.50 on Friday. The stock has a market capitalization of $2.82 billion, a PE ratio of -34.26 and a beta of 2.18. Adaptive Biotechnologies has a 12-month low of $6.26 and a 12-month high of $20.76. The company has a 50 day moving average price of $17.29 and a two-hundred day moving average price of $15.02.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. Adaptive Biotechnologies’s revenue for the quarter was up 102.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.22) EPS. As a group, equities analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insider Buying and Selling

In other news, Director Robert Hershberg sold 22,968 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $16.00, for a total transaction of $367,488.00. Following the sale, the director owned 46,722 shares of the company’s stock, valued at approximately $747,552. This trade represents a 32.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kyle Piskel sold 4,290 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $18.00, for a total value of $77,220.00. Following the sale, the chief financial officer owned 216,637 shares in the company, valued at approximately $3,899,466. This represents a 1.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 1,442,530 shares of company stock worth $24,610,748. 6.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of ADPT. Ameriprise Financial Inc. raised its stake in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Geode Capital Management LLC increased its stake in Adaptive Biotechnologies by 15.6% in the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock valued at $37,461,000 after acquiring an additional 434,347 shares during the period. Aristotle Atlantic Partners LLC raised its position in Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after purchasing an additional 247,402 shares in the last quarter. Jennison Associates LLC raised its position in Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after purchasing an additional 1,363,181 shares in the last quarter. Finally, Fred Alger Management LLC lifted its stake in Adaptive Biotechnologies by 6.7% during the third quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock worth $37,613,000 after purchasing an additional 158,807 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.